CI
PRTK

Cowen Inc’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Cowen Inc’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-2,758
Closed -$100K – 291
2013
Q2 		$100K Buy
+2,758
New +$118K 0.01% 241

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Cowen Inc's PRTK Position: Q3 2013 in Review

Cowen Inc sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2013, closing a stake of 2,758 shares — an estimated $100K sold.

Cowen Inc first reported a position in PRTK in Q2 2013 and held it in 1 quarter. The position peaked at $100K in Q2 2013. 42 funds tracked by Wall St. Rank hold PRTK as of Q3 2013.

  • Cowen Inc reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2013 after selling out during the quarter.
  • Cowen Inc sold 2,758 Paratek Pharmaceuticals, Inc. shares in Q3 2013, an estimated $100K.
  • Cowen Inc first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 1 quarter.
  • Cowen Inc's Paratek Pharmaceuticals, Inc. position peaked at $100K in Q2 2013.
  • 42 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2013.

Based on Cowen Inc's 13F filing for Q3 2013, filed 15 Nov 2013.